BDTX | tickerfilter.com

Fundamental analysis

24%

Profitability 41%

Dept financing 22%

Liquidity 50%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-9.09%

1 Month

33.00%

3 Months

2.66%

6 Months

-29.32%

1 Year

68.75%

2 Year

-53.96%

Key data

Stock price

$2.70

P/E Ratio

N/A

DAY RANGE

$2.68 - $2.94

EPS

$0.30

52 WEEK RANGE

$1.46 - $4.94

52 WEEK CHANGE

$58.82

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

57.289 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

3.14

PUBLIC FLOAT

AVERAGE 10 VOLUME

$917,476

AVERAGE 30 VOLUME

$835,130

Company detail

CEO: David M. Epstein
Region: US
Website: blackdiamondtherapeutics.com
Employees: 90
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Black Diamond Therapeutics, Inc. discovers, develops, and commercializes medicines for patients with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by non-canonical epidermal growth factor receptor (EGFR) mutations. The company is also developing a brain-penetrant inhibitor of EGFR mutations.

BDTX - Black Diamond Therapeutics, Inc.